Is Energy Transfer a Good Dividend Stock to Buy Now?
Energy Transfer (NYSE:ET) offers an impressive yield, to say the…
Buy
62
BUGDF Quote, Financials, Valuation and Earnings
Last price:
$7.91
Seasonality move
:
3.39%
Day range:
$7.91 - $7.91
52-week range:
$6.40 - $7.91
Dividend yield:
1.86%
P/E ratio:
31.15x
P/S ratio:
9.41x
P/B ratio:
7.82x
Volume:
--
Avg. volume:
--
1-year change:
22.88%
Market cap:
$6.3B
Revenue:
$729.3M
EPS (TTM):
$0.25
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BUGDF
Bumrungrad Hospital PCL
|
-- | -- | -- | -- | -- |
|
AMS
American Shared Hospital Services
|
$8.6M | $0.04 | 18.76% | -92.73% | $4.84 |
|
BDUUF
Bangkok Dusit Medical Services PCL
|
-- | -- | -- | -- | -- |
|
CVM
CEL-SCI
|
-- | -- | -- | -- | $8.00 |
|
IGC
IGC Pharma
|
$305K | -$0.02 | 3.39% | -50% | $3.88 |
|
NIVF
NewGenIvf Group
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BUGDF
Bumrungrad Hospital PCL
|
$7.91 | -- | $6.3B | 31.15x | $0.09 | 1.86% | 9.41x |
|
AMS
American Shared Hospital Services
|
$2.71 | $4.84 | $17.5M | 7.97x | $0.00 | 0% | 0.64x |
|
BDUUF
Bangkok Dusit Medical Services PCL
|
$0.66 | -- | $10.5B | 22.90x | $0.01 | 3.37% | 3.42x |
|
CVM
CEL-SCI
|
$0.31 | $8.00 | $23.6M | -- | $0.00 | 0% | -- |
|
IGC
IGC Pharma
|
$0.28 | $3.88 | $22.3M | -- | $0.00 | 0% | 16.43x |
|
NIVF
NewGenIvf Group
|
$0.40 | -- | $682.8K | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BUGDF
Bumrungrad Hospital PCL
|
0.09% | -0.086 | 0.01% | 4.21x |
|
AMS
American Shared Hospital Services
|
45.9% | 0.382 | 90.05% | 1.35x |
|
BDUUF
Bangkok Dusit Medical Services PCL
|
9.5% | 0.255 | 2.47% | 0.94x |
|
CVM
CEL-SCI
|
-- | 1.752 | -- | -- |
|
IGC
IGC Pharma
|
2.1% | -1.475 | 0.51% | 0.21x |
|
NIVF
NewGenIvf Group
|
-- | 0.000 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BUGDF
Bumrungrad Hospital PCL
|
$94.5M | $62.3M | 29.88% | 29.91% | 33.84% | $59.5M |
|
AMS
American Shared Hospital Services
|
$1.4M | -$553K | 8.36% | 13.75% | -3.47% | -$407K |
|
BDUUF
Bangkok Dusit Medical Services PCL
|
$304.7M | $156.2M | 14.33% | 15.75% | 19.66% | $11.1M |
|
CVM
CEL-SCI
|
-- | -$6.9M | -- | -- | -- | -$4.2M |
|
IGC
IGC Pharma
|
$104K | -$1.9M | -114.2% | -116.24% | -730.74% | -$1.4M |
|
NIVF
NewGenIvf Group
|
-- | -- | -- | -- | -- | -- |
Bumrungrad Hospital PCL vs. Competitors
-
Which has Higher Returns BUGDF or AMS?
American Shared Hospital Services has a net margin of 29.4% compared to Bumrungrad Hospital PCL's net margin of -2.96%. Bumrungrad Hospital PCL's return on equity of 29.91% beat American Shared Hospital Services's return on equity of 13.75%.
Company Gross Margin Earnings Per Share Invested Capital BUGDFBumrungrad Hospital PCL49.65% $0.06 $814M AMSAmerican Shared Hospital Services19.57% -$0.03 $54.2M -
What do Analysts Say About BUGDF or AMS?
Bumrungrad Hospital PCL has a consensus price target of --, signalling downside risk potential of --. On the other hand American Shared Hospital Services has an analysts' consensus of $4.84 which suggests that it could grow by 78.6%. Given that American Shared Hospital Services has higher upside potential than Bumrungrad Hospital PCL, analysts believe American Shared Hospital Services is more attractive than Bumrungrad Hospital PCL.
Company Buy Ratings Hold Ratings Sell Ratings BUGDFBumrungrad Hospital PCL0 0 0 AMSAmerican Shared Hospital Services0 0 0 -
Is BUGDF or AMS More Risky?
Bumrungrad Hospital PCL has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison American Shared Hospital Services has a beta of 0.424, suggesting its less volatile than the S&P 500 by 57.593%.
-
Which is a Better Dividend Stock BUGDF or AMS?
Bumrungrad Hospital PCL has a quarterly dividend of $0.09 per share corresponding to a yield of 1.86%. American Shared Hospital Services offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bumrungrad Hospital PCL pays 52.75% of its earnings as a dividend. American Shared Hospital Services pays out -- of its earnings as a dividend. Bumrungrad Hospital PCL's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BUGDF or AMS?
Bumrungrad Hospital PCL quarterly revenues are $190.3M, which are larger than American Shared Hospital Services quarterly revenues of $7M. Bumrungrad Hospital PCL's net income of $55.9M is higher than American Shared Hospital Services's net income of -$207K. Notably, Bumrungrad Hospital PCL's price-to-earnings ratio is 31.15x while American Shared Hospital Services's PE ratio is 7.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bumrungrad Hospital PCL is 9.41x versus 0.64x for American Shared Hospital Services. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BUGDFBumrungrad Hospital PCL9.41x 31.15x $190.3M $55.9M AMSAmerican Shared Hospital Services0.64x 7.97x $7M -$207K
-
Which has Higher Returns BUGDF or BDUUF?
Bangkok Dusit Medical Services PCL has a net margin of 29.4% compared to Bumrungrad Hospital PCL's net margin of 15.81%. Bumrungrad Hospital PCL's return on equity of 29.91% beat Bangkok Dusit Medical Services PCL's return on equity of 15.75%.
Company Gross Margin Earnings Per Share Invested Capital BUGDFBumrungrad Hospital PCL49.65% $0.06 $814M BDUUFBangkok Dusit Medical Services PCL37.83% $0.01 $3.3B -
What do Analysts Say About BUGDF or BDUUF?
Bumrungrad Hospital PCL has a consensus price target of --, signalling downside risk potential of --. On the other hand Bangkok Dusit Medical Services PCL has an analysts' consensus of -- which suggests that it could fall by --. Given that Bumrungrad Hospital PCL has higher upside potential than Bangkok Dusit Medical Services PCL, analysts believe Bumrungrad Hospital PCL is more attractive than Bangkok Dusit Medical Services PCL.
Company Buy Ratings Hold Ratings Sell Ratings BUGDFBumrungrad Hospital PCL0 0 0 BDUUFBangkok Dusit Medical Services PCL0 0 0 -
Is BUGDF or BDUUF More Risky?
Bumrungrad Hospital PCL has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Bangkok Dusit Medical Services PCL has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.674%.
-
Which is a Better Dividend Stock BUGDF or BDUUF?
Bumrungrad Hospital PCL has a quarterly dividend of $0.09 per share corresponding to a yield of 1.86%. Bangkok Dusit Medical Services PCL offers a yield of 3.37% to investors and pays a quarterly dividend of $0.01 per share. Bumrungrad Hospital PCL pays 52.75% of its earnings as a dividend. Bangkok Dusit Medical Services PCL pays out 69.55% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BUGDF or BDUUF?
Bumrungrad Hospital PCL quarterly revenues are $190.3M, which are smaller than Bangkok Dusit Medical Services PCL quarterly revenues of $805.5M. Bumrungrad Hospital PCL's net income of $55.9M is lower than Bangkok Dusit Medical Services PCL's net income of $127.4M. Notably, Bumrungrad Hospital PCL's price-to-earnings ratio is 31.15x while Bangkok Dusit Medical Services PCL's PE ratio is 22.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bumrungrad Hospital PCL is 9.41x versus 3.42x for Bangkok Dusit Medical Services PCL. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BUGDFBumrungrad Hospital PCL9.41x 31.15x $190.3M $55.9M BDUUFBangkok Dusit Medical Services PCL3.42x 22.90x $805.5M $127.4M
-
Which has Higher Returns BUGDF or CVM?
CEL-SCI has a net margin of 29.4% compared to Bumrungrad Hospital PCL's net margin of --. Bumrungrad Hospital PCL's return on equity of 29.91% beat CEL-SCI's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BUGDFBumrungrad Hospital PCL49.65% $0.06 $814M CVMCEL-SCI-- -$0.11 -- -
What do Analysts Say About BUGDF or CVM?
Bumrungrad Hospital PCL has a consensus price target of --, signalling downside risk potential of --. On the other hand CEL-SCI has an analysts' consensus of $8.00 which suggests that it could grow by 2514.38%. Given that CEL-SCI has higher upside potential than Bumrungrad Hospital PCL, analysts believe CEL-SCI is more attractive than Bumrungrad Hospital PCL.
Company Buy Ratings Hold Ratings Sell Ratings BUGDFBumrungrad Hospital PCL0 0 0 CVMCEL-SCI1 0 0 -
Is BUGDF or CVM More Risky?
Bumrungrad Hospital PCL has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI has a beta of 0.951, suggesting its less volatile than the S&P 500 by 4.939%.
-
Which is a Better Dividend Stock BUGDF or CVM?
Bumrungrad Hospital PCL has a quarterly dividend of $0.09 per share corresponding to a yield of 1.86%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bumrungrad Hospital PCL pays 52.75% of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend. Bumrungrad Hospital PCL's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BUGDF or CVM?
Bumrungrad Hospital PCL quarterly revenues are $190.3M, which are larger than CEL-SCI quarterly revenues of --. Bumrungrad Hospital PCL's net income of $55.9M is higher than CEL-SCI's net income of -$7.1M. Notably, Bumrungrad Hospital PCL's price-to-earnings ratio is 31.15x while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bumrungrad Hospital PCL is 9.41x versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BUGDFBumrungrad Hospital PCL9.41x 31.15x $190.3M $55.9M CVMCEL-SCI-- -- -- -$7.1M
-
Which has Higher Returns BUGDF or IGC?
IGC Pharma has a net margin of 29.4% compared to Bumrungrad Hospital PCL's net margin of -711.67%. Bumrungrad Hospital PCL's return on equity of 29.91% beat IGC Pharma's return on equity of -116.24%.
Company Gross Margin Earnings Per Share Invested Capital BUGDFBumrungrad Hospital PCL49.65% $0.06 $814M IGCIGC Pharma40.47% -$0.02 $6.4M -
What do Analysts Say About BUGDF or IGC?
Bumrungrad Hospital PCL has a consensus price target of --, signalling downside risk potential of --. On the other hand IGC Pharma has an analysts' consensus of $3.88 which suggests that it could grow by 1286.4%. Given that IGC Pharma has higher upside potential than Bumrungrad Hospital PCL, analysts believe IGC Pharma is more attractive than Bumrungrad Hospital PCL.
Company Buy Ratings Hold Ratings Sell Ratings BUGDFBumrungrad Hospital PCL0 0 0 IGCIGC Pharma2 0 0 -
Is BUGDF or IGC More Risky?
Bumrungrad Hospital PCL has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IGC Pharma has a beta of 1.449, suggesting its more volatile than the S&P 500 by 44.948%.
-
Which is a Better Dividend Stock BUGDF or IGC?
Bumrungrad Hospital PCL has a quarterly dividend of $0.09 per share corresponding to a yield of 1.86%. IGC Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bumrungrad Hospital PCL pays 52.75% of its earnings as a dividend. IGC Pharma pays out -- of its earnings as a dividend. Bumrungrad Hospital PCL's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BUGDF or IGC?
Bumrungrad Hospital PCL quarterly revenues are $190.3M, which are larger than IGC Pharma quarterly revenues of $257K. Bumrungrad Hospital PCL's net income of $55.9M is higher than IGC Pharma's net income of -$1.8M. Notably, Bumrungrad Hospital PCL's price-to-earnings ratio is 31.15x while IGC Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bumrungrad Hospital PCL is 9.41x versus 16.43x for IGC Pharma. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BUGDFBumrungrad Hospital PCL9.41x 31.15x $190.3M $55.9M IGCIGC Pharma16.43x -- $257K -$1.8M
-
Which has Higher Returns BUGDF or NIVF?
NewGenIvf Group has a net margin of 29.4% compared to Bumrungrad Hospital PCL's net margin of --. Bumrungrad Hospital PCL's return on equity of 29.91% beat NewGenIvf Group's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BUGDFBumrungrad Hospital PCL49.65% $0.06 $814M NIVFNewGenIvf Group-- -- -- -
What do Analysts Say About BUGDF or NIVF?
Bumrungrad Hospital PCL has a consensus price target of --, signalling downside risk potential of --. On the other hand NewGenIvf Group has an analysts' consensus of -- which suggests that it could fall by --. Given that Bumrungrad Hospital PCL has higher upside potential than NewGenIvf Group, analysts believe Bumrungrad Hospital PCL is more attractive than NewGenIvf Group.
Company Buy Ratings Hold Ratings Sell Ratings BUGDFBumrungrad Hospital PCL0 0 0 NIVFNewGenIvf Group0 0 0 -
Is BUGDF or NIVF More Risky?
Bumrungrad Hospital PCL has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NewGenIvf Group has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BUGDF or NIVF?
Bumrungrad Hospital PCL has a quarterly dividend of $0.09 per share corresponding to a yield of 1.86%. NewGenIvf Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bumrungrad Hospital PCL pays 52.75% of its earnings as a dividend. NewGenIvf Group pays out -- of its earnings as a dividend. Bumrungrad Hospital PCL's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BUGDF or NIVF?
Bumrungrad Hospital PCL quarterly revenues are $190.3M, which are larger than NewGenIvf Group quarterly revenues of --. Bumrungrad Hospital PCL's net income of $55.9M is higher than NewGenIvf Group's net income of --. Notably, Bumrungrad Hospital PCL's price-to-earnings ratio is 31.15x while NewGenIvf Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bumrungrad Hospital PCL is 9.41x versus -- for NewGenIvf Group. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BUGDFBumrungrad Hospital PCL9.41x 31.15x $190.3M $55.9M NIVFNewGenIvf Group-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Did the Market Bottom Already?
The past few weeks have been among the most volatile…
Will NVIDIA Return to Its 52-Week High?
NVIDIA (NASDAQ:NVDA) has been among the best-performing investments of the…
Stock Ideas
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Sell
50
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Buy
52
RGC alert for Apr 14
Regencell Bioscience Holdings [RGC] is down 11.8% over the past day.
Buy
52
SLP alert for Apr 14
Simulations Plus [SLP] is up 4.69% over the past day.
Sell
38
ZLAB alert for Apr 14
Zai Lab [ZLAB] is up 6.77% over the past day.
